Dr. Xin Du (杜新) is a regulatory professional with unique combination of FDA and industry regulatory experience as well as international regulation knowledge and experience. He obtained his Ph.D degree from the University of Florida and completed his post-doctoral training at the National Institute of Health (NIH). He worked for US FDA, and pharmaceutical companies of Aventis-Pastuer, Wyeth, Novartis, BMS, NPS, Actinium, Advaxis and Adlai Nortye. Currently, he is the CEO of Evergreen Therapeutics Inc and serves as Director of SAPA Board and Secretary General of FDA Expert Association.
杜新
